Massive data dive: could old gout drugs shield against Alzheimer's?
NCT ID NCT04746989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at health records from nearly 295,000 older adults with gout to see if two common gout medications, probenecid and allopurinol, affect the risk of developing dementia or Alzheimer's disease. The goal was to find out if one drug might be better at protecting the brain. Because this was a data analysis study, it did not involve new treatments or direct patient contact.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to tame stubborn gout flares
- Timing matters: study tests if starting gout drug during a flare is safe
- Ultrasound may solve arthritis diagnosis puzzle
- Probiotic supplement shows promise for gout prevention in small study
- New gout drug dotinurad shows promise in early trial
- Why is gout so common in polynesians? scientists look to genes for answers